Bionano Genomics (BNGO): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The EV/EBITDA multiples for Bionano Genomics, Inc. (BNGO) shown below stand at 0.00, which correlates with the expansion of the Saphyr installation network. Bionano Genomics, Inc. (BNGO) is recognized as an expert in visualizing structural genome anomalies that are inaccessible via standard analysis. The business relies on the long-term implementation of specialized software within research centers, aiming to secure a dominant position in the digital DNA analysis segment.
Analytical breakdowns and data insights for company Bionano Genomics (BNGO)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Total Debt to Capital Bionano Genomics, Inc.|BNGO - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Bionano Genomics|BNGO - Company Cumulative Debt|Debt to Book Capitalization Ratio Bionano|BNGO - Company Long-Term Indebtedness|Company Short-Term Debt Bionano Genomics|Quick Liquidity bionanogenomics.com
- business earnings and investment ratios data:
BNGO - Net Income|Projected Future Earnings Bionano Genomics, Inc.|BNGO - Business Payback Period|Forward P/E Multiple Bionano Genomics, Inc.|BNGO - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano|BNGO - Operating income before deduction of amortization|Net earnings per share for the last 12 months Bionano Genomics|BNGO - Earnings per share for the trailing year|Quarterly EPS earnings growth bionanogenomics.com|BNGO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Bionano Genomics, Inc.
- revenue and sales details:
Initial company analysis:BNGO (Bionano Genomics Inc.)
Bionano Genomics, Inc. (BNGO), the developer of Saphyr systems, is optimizing expenses to combat negative cash flow, making debt load control critical. This metric compares the total enterprise value, including debt, against operating profitability, reflecting the company's resilience to credit risks. The price action of the EV/EBITDA multiple helps investors identify oversold levels or default risks.
Competitor analysis for Bionano Genomics, Inc.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Sionna Pharma - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA (Taysha Gene Therapies) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO Inc - EV/EBITDA Multiple|Company Value to EBITDA Solid Corp|Ocugen (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Pacific Biosciences|Enterprise Value to EBITDA Ratio BNTC|Enterprise Value to EBITDA Ratio Design Therapeutics Inc (DSGN)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Enterprise Value to EBITDA Ratio|KRRO: Enterprise Value to Operating Income Before Depreciation|Editas Corp - EV/EBITDA Multiple|SLN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRQR (ProQR) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation CDXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization sangamo.com|Enterprise Value to Operating Income Before Depreciation NAUT (Nautilus Biotechnology)|EV/EBITDA Multiple MGX|Total Company Value to Operating Income Before Depreciation Ratio Precision BioSciences Inc.|EV/EBITDA Multiple GBIO (Generation Bio Co)|EV/EBITDA Multiple Boundless Bio, Inc BOLD|Exicure Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Imunon IMNN|PHIO: EV/EBITDA Multiple|MBIO: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TransCode Therapeutics, Inc.|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc
